{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-021096","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.332073+00:00","generated_at":"2026-06-01T09:30:42.995093+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enveric Biosciences regains Nasdaq equity compliance; bid price deficiency remains","bullets":["Received Nasdaq letter on May 21, 2024 confirming compliance with minimum stockholders' equity requirement.","Stockholders' equity as of March 31, 2024 was $6,481,856.","Minimum bid price deficiency under Nasdaq Rule 5550(a)(2) remains outstanding.","Company intends to monitor bid price and consider available options to resolve the deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-021096","json":"https://secwatch.observer/filing/0001493152-24-021096.json","markdown":"https://secwatch.observer/filing/0001493152-24-021096.md","text":"https://secwatch.observer/filing/0001493152-24-021096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224021096/0001493152-24-021096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224021096/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:30:42.995093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}